The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...
independence and transparency in Canada’s drug approval process. COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed ...